{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-073437","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.691734+00:00","generated_at":"2026-05-15T23:37:57.777684+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Wave Life Sciences Q4 net loss $53.2M; cash $602.1M; WVE-007 obesity data update expected Q1 2026","bullets":["Net loss $53.2M in Q4 vs income $29.3M YoY; full year loss $204.4M vs $97.0M.","Cash $602.1M as of Dec 31, 2025, up from $302.1M; runway into 3Q 2028.","WVE-007 obesity: INLIGHT Phase 1 showed fat loss similar to GLP-1 at 240mg; Phase 2a multidose planned 1H 2026.","WVE-006 for AATD: regulatory engagement for accelerated approval; feedback expected mid-2026; 400mg multidose data in Q1 2026.","GSK collaboration selected fourth program in Jan 2026; eligible for up to $2.8B milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-073437","json":"https://secwatch.observer/filing/0001193125-26-073437.json","markdown":"https://secwatch.observer/filing/0001193125-26-073437.md","text":"https://secwatch.observer/filing/0001193125-26-073437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526073437/0001193125-26-073437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526073437/d103046d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:37:57.777684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}